Burchert, A., Nicolini, F. E., le Coutre, P., Saußele, S., Hochhaus, A., Tuere, E., . . . Michel, C. (2026). Randomized phase 3 trial of ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Leukemia, 40(2), . https://doi.org/10.1038/s41375-025-02859-1
Chicago-Zitierstil (17. Ausg.)Burchert, Andreas, et al. "Randomized Phase 3 Trial of Ropeginterferon Alfa-2b Versus Surveillance After Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia (ENDURE/CML-IX)." Leukemia 40, no. 2 (2026). https://doi.org/10.1038/s41375-025-02859-1.
MLA-Zitierstil (9. Ausg.)Burchert, Andreas, et al. "Randomized Phase 3 Trial of Ropeginterferon Alfa-2b Versus Surveillance After Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia (ENDURE/CML-IX)." Leukemia, vol. 40, no. 2, 2026, https://doi.org/10.1038/s41375-025-02859-1.